Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Takeda will pay 4 billion dollars upfront and up to 2 billion in sales milestones to acquire Nimbus Therapeutics' TYK2 inhibitor subsidiary, the Japanese…
Takeda Pharmaceutical said on Tuesday it would acquire the TYK2 inhibitor program of Nimbus Therapeutics in a deal worth up to 6 billion dollars, paying…
Phase 3 plaque-psoriasis topline (Dec 18 2025): zasocitinib (TAK-279) met co-primary endpoints sPGA 0/1 and PASI 75 at wk16, superior to apremilast on ranked…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Takeda acquired Nimbus's TYK2 subsidiary (Nimbus Lakshmi) and its oral, highly selective allosteric TYK2 inhibitor NDI-034858 (TAK-279) for ~$4B upfront plus up to $2B in sales milestones (two $1B tranches at $4B and $5B annual net sales of TAK-279-derived products), total deal up to $6B. The deal was announced Dec 13, 2022 and closed Feb 8, 2023 after FTC clearance. The asset has since received the INN zasocitinib. In December 2025 Takeda reported positive topline results from two pivotal Phase 3 plaque-psoriasis studies: zasocitinib met both co-primary endpoints (sPGA 0/1 and PASI 75 at week 16) and beat active comparator apremilast on all ranked secondary endpoints, with ~70% of patients achieving clear/almost-clear skin (sPGA 0/1). Zasocitinib is also in Phase 3 development for psoriatic arthritis. Takeda plans to begin a U.S. NDA and other regulatory submissions in fiscal year 2026 — validating the deal thesis of acquiring a late-stage oral immunology asset positioned against the multi-billion-dollar TYK2/oral-psoriasis market.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Nimbus Therapeutics (Lakshmi subsidiary, TYK2 program) (this deal) | 2022 | $6.0B | — |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2022 deals · Takeda Pharmaceutical Company Ltd. deals · Dermatology deals